Literature DB >> 26985142

Cost and resource utilization in cervical cancer management: a real-world retrospective cost analysis.

I Cromwell1, Z Ferreira1, L Smith2, K van der Hoek1, G Ogilvie3, A Coldman2, S J Peacock4.   

Abstract

OBJECTIVES: We set out to assess the health care resource utilization and cost of cervical cancer from the perspective of a single-payer health care system.
METHODS: Retrospective observational data for women diagnosed with cervical cancer in British Columbia between 2004 and 2009 were analyzed to calculate patient-level resource utilization patterns from diagnosis to death or 5-year discharge. Domains of resource use within the scope of this cost analysis were chemotherapy, radiotherapy, and brachytherapy administered by the BC Cancer Agency; resource utilization related to hospitalization and outpatient visits as recorded by the B.C. Ministry of Health; medically required services billed under the B.C. Medical Services Plan; and prescriptions dispensed under British Columbia's health insurance programs. Unit costs were applied to radiotherapy and brachytherapy, producing per-patient costs.
RESULTS: The mean cost per case of treating cervical cancer in British Columbia was $19,153 (standard error: $3,484). Inpatient hospitalizations, at 35%, represented the largest proportion of the total cost (95% confidence interval: 32.9% to 36.9%). Costs were compared for subgroups of the total cohort.
CONCLUSIONS: As health care systems change the way they manage, screen for, and prevent cervical cancer, cost-effectiveness evaluations of the overall approach will require up-to-date data for resource utilization and costs. We provide information suitable for such a purpose and also identify factors that influence costs.

Entities:  

Keywords:  Cost of care; cervical cancer

Year:  2016        PMID: 26985142      PMCID: PMC4780585          DOI: 10.3747/co.23.2914

Source DB:  PubMed          Journal:  Curr Oncol        ISSN: 1198-0052            Impact factor:   3.677


  20 in total

1.  Stage-specific treatment costs for cervical cancer in the United Kingdom.

Authors:  J L Wolstenholme; D K Whynes
Journal:  Eur J Cancer       Date:  1998-11       Impact factor: 9.162

Review 2.  Evaluation of cervical cytology.

Authors:  D C McCrory; D B Matchar; L Bastian; S Datta; V Hasselblad; J Hickey; E Myers; K Nanda
Journal:  Evid Rep Technol Assess (Summ)       Date:  1999-01

3.  Characterizing single-molecule FRET dynamics with probability distribution analysis.

Authors:  Yusdi Santoso; Joseph P Torella; Achillefs N Kapanidis
Journal:  Chemphyschem       Date:  2010-07-12       Impact factor: 3.102

4.  [Invasive cervical cancer treatment costs in France].

Authors:  Patrick Arveux; Stève Bénard; Stéphane Bouée; Antoine Lafuma; Laurent Martin; Ludovic Cravello; Vanessa Rémy; J Gabrielle Breugelmans
Journal:  Bull Cancer       Date:  2007-02       Impact factor: 1.276

5.  Improved survival with bevacizumab in advanced cervical cancer.

Authors:  Krishnansu S Tewari; Michael W Sill; Harry J Long; Richard T Penson; Helen Huang; Lois M Ramondetta; Lisa M Landrum; Ana Oaknin; Thomas J Reid; Mario M Leitao; Helen E Michael; Bradley J Monk
Journal:  N Engl J Med       Date:  2014-02-20       Impact factor: 91.245

6.  Economic burden associated with the management of cervical cancer, cervical dysplasia and genital warts in Belgium.

Authors:  Lieven Annemans; Vanessa Rémy; Emilie Lamure; Erik Spaepen; Mark Lamotte; Jean-Paul Muchada; Nathalie Largeron
Journal:  J Med Econ       Date:  2008       Impact factor: 2.448

7.  Healthcare resource use and costs associated with cervical, vaginal and vulvar cancers in a large U.S. health plan.

Authors:  Ralph P Insinga; Xin Ye; Puneet K Singhal; George W Carides
Journal:  Gynecol Oncol       Date:  2008-08-30       Impact factor: 5.482

8.  Understanding the costs of cancer care before and after diagnosis for the 21 most common cancers in Ontario: a population-based descriptive study.

Authors:  Claire de Oliveira; Karen E Bremner; Reka Pataky; Nadia Gunraj; Kelvin Chan; Stuart Peacock; Murray D Krahn
Journal:  CMAJ Open       Date:  2013-01-16

9.  Reduced cervical cancer incidence and mortality in Canada: national data from 1932 to 2006.

Authors:  James A Dickinson; Agata Stankiewicz; Cathy Popadiuk; Lisa Pogany; Jay Onysko; Anthony B Miller
Journal:  BMC Public Health       Date:  2012-11-16       Impact factor: 3.295

10.  Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials.

Authors:  Guglielmo Ronco; Joakim Dillner; K Miriam Elfström; Sara Tunesi; Peter J F Snijders; Marc Arbyn; Henry Kitchener; Nereo Segnan; Clare Gilham; Paolo Giorgi-Rossi; Johannes Berkhof; Julian Peto; Chris J L M Meijer
Journal:  Lancet       Date:  2013-11-03       Impact factor: 79.321

View more
  2 in total

1.  Medical Cost to Treat Cervical Cancer Patients at a Social Security Third Level Oncology Hospital in Mexico City

Authors:  Víctor Granados-García; Patricia Piña-Sánchez; Nancy Reynoso-Noveron; Yvonne N Flores; Filiberto Toledano-Toledano; Gloria Estrada-Gómez; Teresa Apresa-García; Arely A Briseño
Journal:  Asian Pac J Cancer Prev       Date:  2019-05-25

2.  Hospitalization burden associated with malignant neoplasia and in situ carcinoma in vulva and vagina during a 5-year period (2009-2013) in Spain: An epidemiological study.

Authors:  Noelia López; Ángel Gil-de-Miguel; Raquel Pascual-García; Jose Manuel Ramón Y Cajal; Ruth Gil-Prieto
Journal:  Papillomavirus Res       Date:  2018-02-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.